Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction
Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clin...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/985460 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563832544821248 |
|---|---|
| author | Annemarie Weissenbacher Theresa Hautz Michael Kimelman Rupert Oberhuber Hanno Ulmer Claudia Bösmüller Manuel Maglione Stefan Schneeberger |
| author_facet | Annemarie Weissenbacher Theresa Hautz Michael Kimelman Rupert Oberhuber Hanno Ulmer Claudia Bösmüller Manuel Maglione Stefan Schneeberger |
| author_sort | Annemarie Weissenbacher |
| collection | DOAJ |
| description | Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clinical course after KTx. This is a single center retrospective analysis of 225 patients/consecutive kidney transplantations treated with alemtuzumab for lymphocyte depletion and 205 recipients treated with basiliximab. Mean lymphocyte counts were 22.8 ± 9.41% before Tx and 2.61 ± 3.11% between week 1 and week 3 in the alemtuzumab group and 23.77 ± 10.42% before Tx and 13.92 ± 8.20% in the basiliximab group. Delayed graft function (DGF), cytomegalovirus (CMV) status, and recipient age showed a significant correlation with lymphocyte counts in the alemtuzumab group only. The outcome was read in reference to the velocity of lymphocyte recovery and in comparison to the control group. Lymphocyte counts early after transplantation, following alemtuzumab treatment, could be identified as a predictive factor for kidney function early after transplantation. A detailed analysis of phenotype and function of lymphocytes after alemtuzumab induction together with a correlation with the clinical course is warranted. |
| format | Article |
| id | doaj-art-273023e5b7a74adf9b0383f8fed8103f |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-273023e5b7a74adf9b0383f8fed8103f2025-02-03T01:12:25ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/985460985460Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab InductionAnnemarie Weissenbacher0Theresa Hautz1Michael Kimelman2Rupert Oberhuber3Hanno Ulmer4Claudia Bösmüller5Manuel Maglione6Stefan Schneeberger7Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, AustriaAlemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clinical course after KTx. This is a single center retrospective analysis of 225 patients/consecutive kidney transplantations treated with alemtuzumab for lymphocyte depletion and 205 recipients treated with basiliximab. Mean lymphocyte counts were 22.8 ± 9.41% before Tx and 2.61 ± 3.11% between week 1 and week 3 in the alemtuzumab group and 23.77 ± 10.42% before Tx and 13.92 ± 8.20% in the basiliximab group. Delayed graft function (DGF), cytomegalovirus (CMV) status, and recipient age showed a significant correlation with lymphocyte counts in the alemtuzumab group only. The outcome was read in reference to the velocity of lymphocyte recovery and in comparison to the control group. Lymphocyte counts early after transplantation, following alemtuzumab treatment, could be identified as a predictive factor for kidney function early after transplantation. A detailed analysis of phenotype and function of lymphocytes after alemtuzumab induction together with a correlation with the clinical course is warranted.http://dx.doi.org/10.1155/2015/985460 |
| spellingShingle | Annemarie Weissenbacher Theresa Hautz Michael Kimelman Rupert Oberhuber Hanno Ulmer Claudia Bösmüller Manuel Maglione Stefan Schneeberger Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction Journal of Immunology Research |
| title | Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction |
| title_full | Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction |
| title_fullStr | Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction |
| title_full_unstemmed | Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction |
| title_short | Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction |
| title_sort | lymphocytes as an indicator for initial kidney function a single center analysis of outcome after alemtuzumab or basiliximab induction |
| url | http://dx.doi.org/10.1155/2015/985460 |
| work_keys_str_mv | AT annemarieweissenbacher lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT theresahautz lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT michaelkimelman lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT rupertoberhuber lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT hannoulmer lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT claudiabosmuller lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT manuelmaglione lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction AT stefanschneeberger lymphocytesasanindicatorforinitialkidneyfunctionasinglecenteranalysisofoutcomeafteralemtuzumaborbasiliximabinduction |